Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Stoke Therapeutics (STOK) Leases (2021 - 2025)

Stoke Therapeutics has reported Leases over the past 5 years, most recently at $3.1 million for Q4 2025.

  • For Q4 2025, Leases fell 28.63% year-over-year to $3.1 million; the TTM value through Dec 2025 reached $3.1 million, down 28.63%, while the annual FY2025 figure was $3.1 million, 28.63% down from the prior year.
  • Leases for Q4 2025 was $3.1 million at Stoke Therapeutics, down from $3.7 million in the prior quarter.
  • Over five years, Leases peaked at $6.1 million in Q1 2024 and troughed at $3.1 million in Q3 2023.
  • A 5-year average of $4.3 million and a median of $4.2 million in 2023 define the central range for Leases.
  • Biggest five-year swings in Leases: tumbled 41.76% in 2023 and later surged 59.79% in 2024.
  • Year by year, Leases stood at $3.5 million in 2021, then surged by 35.8% to $4.8 million in 2022, then decreased by 13.74% to $4.1 million in 2023, then grew by 5.98% to $4.3 million in 2024, then decreased by 28.63% to $3.1 million in 2025.
  • Business Quant data shows Leases for STOK at $3.1 million in Q4 2025, $3.7 million in Q3 2025, and $3.2 million in Q2 2025.